Vol. 2 No. 4 (2022)
Reimbursement Reviews

Inclisiran (Leqvio)

Published April 19, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses inclisiran (Leqvio), 284 mg in 1.5 mL (189 mg/mL) solution for SC injection.
  • Indication: As an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) level in adults with the following conditions who are on a maximally tolerated dose of a statin, with or without other LDL-C-lowering therapies:
    • heterozygous familial hypercholesterolemia (HeFH), or
    • non-familial hypercholesterolemia with atherosclerotic cardiovascular disease.